BLTE 6-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

BLTE ▼ -16.56% at T+20d

LONG call ✗ call lost -16.56% · α vs SPY -19.72% · entry $167.42 → $139.70

Next anchor: T+60d in 5w

Last close $139.63 (close Jun 8) · -16.60% from $167.42 entry

Entry anchored
Apr 21, 03:59 PM ET
via Databento tick

T+1d

-1.77%

call -1.77% · α -1.38%

$164.45

settled 7w ago

T+5d

-5.47%

call -5.47% · α -5.52%

$158.27

settled 6w ago

T+20d

-16.56%

call -16.56% · α -19.72%

$139.70

settled 22d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Belite Bio announced the initiation of a rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, an investigational therapy for Stargardt disease type 1, supported by Breakthrough Therapy Designation. The company expects to complete the submission in Q2 2026.

Actionable Insight

This is a significant regulatory milestone that increases the likelihood of tinlarebant becoming the first approved treatment for Stargardt disease. Traders should monitor FDA feedback and the completion of the NDA review process, as approval could drive substantial valuation upside. Consider positioning ahead of potential PDUFA date announcements.

Key Facts

Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
The NDA submission is supported by Breakthrough Therapy Designation and data from the Phase 3 DRAGON trial.
The company expects to complete the submission in Q2 2026.
Tinlarebant has also received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA.
Management is advancing commercialization planning in anticipation of a potential U.S. launch.

Financial Impact

No immediate financial impact disclosed, but regulatory progress increases the probability of future revenue from potential approval and commercialization.

revenuevaluationpipeline value

Risk Factors

FDA may require additional data or reject the NDA, delaying or preventing approval.
Clinical data may not be sufficient to support approval despite Breakthrough Therapy Designation.
Commercialization timelines and market adoption remain uncertain.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001104659-26-045989
Document: tm2611999d1_6k.htm	0001104659-26-045989
Document: 0001104659-26-045989-index-headers.html	0001104659-26-045989
Document: 0001104659-26-045989-index.html	0001104659-26-045989
Document: 0001104659-26-045989.txt	0001104659-26-045989

6 reports for BLTE

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +13.78%Apr 9, 2026

Filters

Reports for BLTE — sortable, filterable
	Type				Now
May 20, 2026 20d ago	Press Release MIXED ★ 6/10	$143.36 $148.00	▲ +3.24%	▲ +1.43%	$139.63 (−2.60%)
Apr 21, 2026 7w ago	6-K BULLISH ★ 8/10	$167.42 $158.27	▼ −5.47%	▼ −5.52%	$139.63 (−16.60%)
Apr 21, 2026 7w ago	Press Release NEUTRAL ★ 5/10	$167.42 $158.27	▼ −5.47%	▼ −5.52%	$139.63 (−16.60%)
Apr 9, 2026 8w ago	Insider Cluster BEARISH ★ 7/10	$181.17 $158.05	▲ +12.76%	▲ +15.95%	$139.63 (+22.93%)
Apr 9, 2026 8w ago	Insider Cluster BEARISH ★ 6/10	$181.17 $158.05	▲ +12.76%	▲ +15.95%	$139.63 (+22.93%)
Mar 2, 2026 14w ago	Press Release BULLISH ★ 9/10	$177.58 $179.12	▲ +0.87%	▲ +2.07%	$139.63 (−21.37%)

US Market Status

Market Closed — Opens in 7h 19m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access